S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
QQQ   296.77 (+0.78%)
AAPL   116.10 (+0.81%)
MSFT   214.00 (+0.07%)
FB   275.67 (-0.45%)
GOOGL   1,767.49 (+0.20%)
AMZN   3,188.35 (+2.25%)
TSLA   573.40 (+3.24%)
NVDA   529.50 (+2.16%)
BABA   277.50 (-0.88%)
CGC   26.84 (-0.48%)
GE   10.48 (+0.29%)
MU   63.42 (-0.83%)
AMD   86.67 (+1.88%)
T   28.99 (-0.82%)
NIO   53.97 (+0.86%)
F   9.09 (-3.81%)
ACB   8.72 (-5.53%)
NFLX   484.51 (+0.34%)
GILD   59.50 (-1.24%)
BA   217.62 (-0.40%)
DIS   149.05 (-1.61%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
QQQ   296.77 (+0.78%)
AAPL   116.10 (+0.81%)
MSFT   214.00 (+0.07%)
FB   275.67 (-0.45%)
GOOGL   1,767.49 (+0.20%)
AMZN   3,188.35 (+2.25%)
TSLA   573.40 (+3.24%)
NVDA   529.50 (+2.16%)
BABA   277.50 (-0.88%)
CGC   26.84 (-0.48%)
GE   10.48 (+0.29%)
MU   63.42 (-0.83%)
AMD   86.67 (+1.88%)
T   28.99 (-0.82%)
NIO   53.97 (+0.86%)
F   9.09 (-3.81%)
ACB   8.72 (-5.53%)
NFLX   484.51 (+0.34%)
GILD   59.50 (-1.24%)
BA   217.62 (-0.40%)
DIS   149.05 (-1.61%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
QQQ   296.77 (+0.78%)
AAPL   116.10 (+0.81%)
MSFT   214.00 (+0.07%)
FB   275.67 (-0.45%)
GOOGL   1,767.49 (+0.20%)
AMZN   3,188.35 (+2.25%)
TSLA   573.40 (+3.24%)
NVDA   529.50 (+2.16%)
BABA   277.50 (-0.88%)
CGC   26.84 (-0.48%)
GE   10.48 (+0.29%)
MU   63.42 (-0.83%)
AMD   86.67 (+1.88%)
T   28.99 (-0.82%)
NIO   53.97 (+0.86%)
F   9.09 (-3.81%)
ACB   8.72 (-5.53%)
NFLX   484.51 (+0.34%)
GILD   59.50 (-1.24%)
BA   217.62 (-0.40%)
DIS   149.05 (-1.61%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
QQQ   296.77 (+0.78%)
AAPL   116.10 (+0.81%)
MSFT   214.00 (+0.07%)
FB   275.67 (-0.45%)
GOOGL   1,767.49 (+0.20%)
AMZN   3,188.35 (+2.25%)
TSLA   573.40 (+3.24%)
NVDA   529.50 (+2.16%)
BABA   277.50 (-0.88%)
CGC   26.84 (-0.48%)
GE   10.48 (+0.29%)
MU   63.42 (-0.83%)
AMD   86.67 (+1.88%)
T   28.99 (-0.82%)
NIO   53.97 (+0.86%)
F   9.09 (-3.81%)
ACB   8.72 (-5.53%)
NFLX   484.51 (+0.34%)
GILD   59.50 (-1.24%)
BA   217.62 (-0.40%)
DIS   149.05 (-1.61%)
Log in
NASDAQ:AYTU

Aytu BioScience Stock Forecast, Price & News

$0.90
+0.02 (+2.61 %)
(As of 11/25/2020 03:50 PM ET)
Add
Compare
Today's Range
$0.87
Now: $0.90▼
$0.91
50-Day Range
$0.91
MA: $1.02▼
$1.35
52-Week Range
$0.34
Now: $0.90▼
$2.99
Volume61,691 shs
Average Volume10.15 million shs
Market Capitalization$115.14 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.23
Aytu BioScience, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension. It also offers ZolpiMist, an oral spray for the treatment of insomnia; and MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen. Aytu BioScience, Inc. is based in Englewood, Colorado.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.35 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AYTU
Previous Symbol
CUSIPN/A
CIKN/A
Webaytubio.com
Phone720-437-6580
Employees75

Debt

Debt-to-Equity Ratio0.12
Current Ratio3.04
Quick Ratio2.51

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$27.63 million
Price / Sales4.17
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.71 per share
Price / Book1.27

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-13,620,000.00
Net Margins-32.73%
Return on Equity-25.20%
Return on Assets-13.80%

Miscellaneous

Outstanding Shares127,929,000
Market Cap$115.14 million
Next Earnings Date2/11/2021 (Estimated)
OptionableNot Optionable
$0.90
+0.02 (+2.61 %)
(As of 11/25/2020 03:50 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AYTU News and Ratings via Email

Sign-up to receive the latest news and ratings for AYTU and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aytu BioScience (NASDAQ:AYTU) Frequently Asked Questions

How has Aytu BioScience's stock price been impacted by Coronavirus?

Aytu BioScience's stock was trading at $1.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AYTU shares have decreased by 33.3% and is now trading at $0.90.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Aytu BioScience?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aytu BioScience in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aytu BioScience.

What stocks does MarketBeat like better than Aytu BioScience?

Wall Street analysts have given Aytu BioScience a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aytu BioScience wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Aytu BioScience's next earnings date?

Aytu BioScience is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for Aytu BioScience.

How were Aytu BioScience's earnings last quarter?

Aytu BioScience, Inc. (NASDAQ:AYTU) posted its quarterly earnings data on Tuesday, November, 17th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.06) by $0.02. Aytu BioScience had a negative return on equity of 25.20% and a negative net margin of 32.73%.
View Aytu BioScience's earnings history.

When did Aytu BioScience's stock split? How did Aytu BioScience's stock split work?

Shares of Aytu BioScience reverse split on the morning of Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 28th 2017. An investor that had 100 shares of Aytu BioScience stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for AYTU?

1 brokers have issued 12-month price targets for Aytu BioScience's stock. Their forecasts range from $3.00 to $3.00. On average, they anticipate Aytu BioScience's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 233.3% from the stock's current price.
View analysts' price targets for Aytu BioScience.

Who are some of Aytu BioScience's key competitors?

Some companies that are related to Aytu BioScience include Crinetics Pharmaceuticals (CRNX), Marinus Pharmaceuticals (MRNS), Akebia Therapeutics (AKBA), Amryt Pharma (AMYT), Prothena (PRTA), RAPT Therapeutics (RAPT), Wave Life Sciences (WVE), Molecular Templates (MTEM), Homology Medicines (FIXX), Puma Biotechnology (PBYI), UroGen Pharma (URGN), Spero Therapeutics (SPRO), Aeglea BioTherapeutics (AGLE), IMARA (IMRA) and Avadel Pharmaceuticals (AVDL).
View all competitors.

What other stocks do shareholders of Aytu BioScience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aytu BioScience investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), ADMA Biologics (ADMA), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), iBio (IBIO), Matinas BioPharma (MTNB), Bionano Genomics (BNGO) and SCYNEXIS (SCYX).

Who are Aytu BioScience's key executives?

Aytu BioScience's management team includes the following people:
  • Mr. Joshua R. Disbrow, Chairman & CEO (Age 45, Pay $792.62k)
  • Mr. David A. Green M.B.A., CPA, CFO, Sec. & Treasurer (Age 57, Pay $550.05k)
  • Mr. Jarrett T. Disbrow Ph.D., Exec. VP of Corp. Devel. (Age 45)
  • Mr. Matthew V. Phillips, Exec. VP of Commercial Operations (Age 52)

What is Aytu BioScience's stock symbol?

Aytu BioScience trades on the NASDAQ under the ticker symbol "AYTU."

Who are Aytu BioScience's major shareholders?

Aytu BioScience's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.36%), State Street Corp (0.23%), Jane Street Group LLC (0.04%), Verdence Capital Advisors LLC (0.04%), JPMorgan Chase & Co. (0.03%) and Beech Hill Advisors Inc. (0.02%). Company insiders that own Aytu BioScience stock include Armistice Capital Master Fund, David A Green and Joshua R Disbrow.
View institutional ownership trends for Aytu BioScience.

Which major investors are selling Aytu BioScience stock?

AYTU stock was sold by a variety of institutional investors in the last quarter, including Jane Street Group LLC, and Verdence Capital Advisors LLC.
View insider buying and selling activity for Aytu BioScience.

Which major investors are buying Aytu BioScience stock?

AYTU stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, LPL Financial LLC, Beech Hill Advisors Inc., and JPMorgan Chase & Co.. Company insiders that have bought Aytu BioScience stock in the last two years include Armistice Capital Master Fund, and Joshua R Disbrow.
View insider buying and selling activity for Aytu BioScience.

How do I buy shares of Aytu BioScience?

Shares of AYTU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aytu BioScience's stock price today?

One share of AYTU stock can currently be purchased for approximately $0.90.

How big of a company is Aytu BioScience?

Aytu BioScience has a market capitalization of $115.14 million and generates $27.63 million in revenue each year. Aytu BioScience employs 75 workers across the globe.

What is Aytu BioScience's official website?

The official website for Aytu BioScience is aytubio.com.

How can I contact Aytu BioScience?

Aytu BioScience's mailing address is 373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-437-6580 or via email at [email protected]

This page was last updated on 11/25/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.